Last reviewed · How we verify
Td5ap
Td5ap, marketed by the Swedish Institute for Infectious Disease Control, holds a niche position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Td5ap |
|---|---|
| Also known as | COVAXiS |
| Sponsor | Swedish Institute for Infectious Disease Control |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Td5ap CI brief — competitive landscape report
- Td5ap updates RSS · CI watch RSS
- Swedish Institute for Infectious Disease Control portfolio CI